Literature DB >> 26294717

Cladribine for mastocytosis: benefits and risks.

Cem Akin1.   

Abstract

In this issue of Blood, Barete et al report the safety and efficacy of cladribine in 68 adult patients with mastocytosis.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26294717     DOI： 10.1182/blood-2015-06-649525

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  3 in total

1.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

Review 2.  Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.

Authors:  Michel Arock; Ghaith Wedeh; Gregor Hoermann; Siham Bibi; Cem Akin; Barbara Peter; Karoline V Gleixner; Karin Hartmann; Joseph H Butterfield; Dean D Metcalfe; Peter Valent
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

3.  Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.

Authors:  Faizan Malik; Naveed Ali; Syed Imran Mustafa Jafri; Ali Ghani; Mohsin Hamid; Margot Boigon; Christian Fidler
Journal:  J Med Case Rep       Date:  2017-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.